Burçak Cavnar Helvacı1, Hüsniye Başer2, Bekir Çakır2. 1. Ankara City Hospital, Department of Endocrinology & Metabolism, Ankara, Turkey. burcakcavnar@gmail.com. 2. Ankara City Hospital, Department of Endocrinology & Metabolism, Ankara, Turkey and Yıldırım Beyazıt University Faculty of Medicine Department of Endocrinology & Metabolism, Ankara, Turkey.
Abstract
The first pump developed by Dr. Kadish and his team in 1963 aimed to "continue subcutaneous insulin infusion". The number of patients using insulin pumps has increased since the 1980s. This historical perspective has labeled pump therapy in endocrinology and metabolism synonymous with insulin pumps. However, certain other hormonal disorders might also benefit from this kind of treatment. Pump therapy is currently the best approach to achieve physiological mimicry. Furthermore, it may help in overcoming pharmacokinetic issues or allergies. Until now, hormone replacement via pumps has been a salvage method for complex cases at the expense of increased costs. However, it is believed that applications of pump treatment will widen in the future owing to the rapidly evolving technology. In this mini review, data on pump use for patients with adrenal insufficiency, hypogonadism, hypoparathyroidism, congenital adrenal hyperplasia, and congenital hyperinsulinism have been briefly summarized. The study has aimed at covering all the relevant clinical studies and important case reports/series. METHODS: A systematic literature search has been conducted on PubMed database seeking articles published until May 2021 using a combination of the following Medical Subject Headings terms and keywords: pump "OR" continue infusion "AND" (adrenal insufficiency "OR" Addison "OR" hydrocortisone "OR" hypoparathyroidism "OR teriparatide" "OR" somatostatin "OR" hypogonadism "OR" hypoglycemia "OR" endocrinology "OR" hormone replacement). In addition, the reference publications in the identified articles have also been reviewed.
The first pump developed by Dr. Kadish and his team in 1963 aimed to "continue subcutaneous insulin infusion". The number of patients using insulin pumps has increased since the 1980s. This historical perspective has labeled pump therapy in endocrinology and metabolism synonymous with insulin pumps. However, certain other hormonal disorders might also benefit from this kind of treatment. Pump therapy is currently the best approach to achieve physiological mimicry. Furthermore, it may help in overcoming pharmacokinetic issues or allergies. Until now, hormone replacement via pumps has been a salvage method for complex cases at the expense of increased costs. However, it is believed that applications of pump treatment will widen in the future owing to the rapidly evolving technology. In this mini review, data on pump use for patients with adrenal insufficiency, hypogonadism, hypoparathyroidism, congenital adrenal hyperplasia, and congenital hyperinsulinism have been briefly summarized. The study has aimed at covering all the relevant clinical studies and important case reports/series. METHODS: A systematic literature search has been conducted on PubMed database seeking articles published until May 2021 using a combination of the following Medical Subject Headings terms and keywords: pump "OR" continue infusion "AND" (adrenal insufficiency "OR" Addison "OR" hydrocortisone "OR" hypoparathyroidism "OR teriparatide" "OR" somatostatin "OR" hypogonadism "OR" hypoglycemia "OR" endocrinology "OR" hormone replacement). In addition, the reference publications in the identified articles have also been reviewed.
Authors: Lucia Gagliardi; Marni A Nenke; Tilenka R J Thynne; Jenny von der Borch; Wayne A Rankin; David E Henley; Jane Sorbello; Warrick J Inder; David J Torpy Journal: J Clin Endocrinol Metab Date: 2014-08-15 Impact factor: 5.958
Authors: Marianne Oksnes; Sigridur Björnsdottir; Magnus Isaksson; Paal Methlie; Siri Carlsen; Roy M Nilsen; Jan-Erik Broman; Kai Triebner; Olle Kämpe; Anna-Lena Hulting; Sophie Bensing; Eystein S Husebye; Kristian Løvås Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Stafford L Lightman; Crispin C Wiles; Helen C Atkinson; David E Henley; Georgina M Russell; Jack A Leendertz; Mervyn A McKenna; Francesca Spiga; Susan A Wood; Becky L Conway-Campbell Journal: Eur J Pharmacol Date: 2008-02-09 Impact factor: 4.432
Authors: Ashwini Mallappa; Ninet Sinaii; Parag Kumar; Martin J Whitaker; Lori-Ann Daley; Dena Digweed; David J A Eckland; Carol Van Ryzin; Lynnette K Nieman; Wiebke Arlt; Richard J Ross; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2014-12-11 Impact factor: 5.958